Report of Consensus Panel 6 from the 11 th International Workshop on Waldenstrom's Macroglobulinemia on Management of Waldenstrom's Macroglobulinemia Related Amyloidosis

Consensus Panel 6 (CP6) of the 11th International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with reviewing the state of the art for diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenstrom macroglobulinemia (WM). Since significant advances have been made in the management of AL amyloidosis an update for this rare disease associated with WM was necessary. The key recommendations from IWWM-11 CP6 included: (1) The need to improve the diagnostic process by recognizing red flags and using biomarkers and imaging; (2) The essential tests for appropriate workup; (3) The diagnostic flowchart, including mandatory amyloid typing, that improves the differential diagnosis with transthyretin amyloidosis; (4) Criteria for therapy response assessment; (5) State of the art of the treatment including therapy of wild type transthyretin amyloidosis associated with WM. & COPY; 2023 Elsevier Inc. All rights reserved.

Automated summary

Consensus Panel 6 (CP6) of IWWM-11 reviewed the state of the art for the diagnosis, prognosis, and therapy of AL amyloidosis associated with Waldenstrom macroglobulinemia (WM), and provided key recommendations including improving the diagnostic process, diagnostic flowchart, therapy response assessment criteria, and treatment options for wild type transthyretin amyloidosis associated with WM.